Bronstein, Gewirtz & Grossman, LLC Investigates Potential Securities Fraud Claims Against Corcept Therapeutics Incorporated
New York, NY – March 11, 2025
Bronstein, Gewirtz & Grossman, LLC is currently investigating potential securities fraud claims against Corcept Therapeutics Incorporated (“Corcept” or “the Company”) (NASDAQ: CORT). The investigation concerns possible breaches of federal securities laws, including claims that Corcept and certain of its executives and directors may have issued materially misleading statements or failed to disclose material information to investors.
Background
Corcept Therapeutics is a biopharmaceutical company that focuses on developing and commercializing drugs for the endocrine system. Its primary product is Korlym, a cortisol synthesis inhibitor indicated for the treatment of Cushing’s syndrome in adults. The drug was approved by the U.S. Food and Drug Administration (FDA) in 2011.
Investigation Details
The investigation is focused on certain statements made by Corcept regarding the commercial potential of Korlym and the Company’s financial performance. Specifically, the firm is looking into whether Corcept misrepresented the market size and growth prospects for Korlym, as well as its financial results and revenue projections.
Potential Impact on Investors
If it is determined that Corcept and its executives and directors made materially false or misleading statements or failed to disclose material information, investors who purchased Corcept securities may be able to recover their losses through a securities class action lawsuit. Such a lawsuit could potentially lead to significant financial compensation for affected investors.
Global Implications
The investigation and potential securities fraud allegations against Corcept could have far-reaching implications for the biopharmaceutical industry as a whole. If it is found that Corcept engaged in fraudulent activities, it could damage the reputation of the industry and potentially lead to increased regulatory scrutiny and stricter reporting requirements for biopharmaceutical companies.
Next Steps
If you are a Corcept investor and believe that you may have lost money as a result of the Company’s alleged securities law violations, you are encouraged to contact Bronstein, Gewirtz & Grossman, LLC to discuss your potential legal rights and options. You can assist the investigation by visiting the firm’s site at bgandg.com/CORT.
The firm’s securities fraud investigation team has extensive experience in representing institutional and individual investors in securities class action lawsuits. The team is dedicated to ensuring that all investors have the information they need to make informed decisions about their investments and hold companies accountable for any wrongdoing.
Conclusion
Investors in Corcept Therapeutics Incorporated who purchased the Company’s securities may have potential claims for securities fraud. The investigation by Bronstein, Gewirtz & Grossman, LLC is focused on possible breaches of federal securities laws, including misrepresentations regarding the commercial potential of Korlym and Corcept’s financial performance. If it is determined that Corcept and its executives and directors made materially false or misleading statements or failed to disclose material information, affected investors may be able to recover their losses through a securities class action lawsuit. The potential implications of this investigation extend beyond Corcept and could impact the biopharmaceutical industry as a whole.
If you are a Corcept investor and believe that you may have lost money as a result of the Company’s alleged securities law violations, you are encouraged to contact Bronstein, Gewirtz & Grossman, LLC to discuss your potential legal rights and options. The firm’s securities fraud investigation team is dedicated to ensuring that all investors have the information they need to make informed decisions and hold companies accountable for any wrongdoing.
- Bronstein, Gewirtz & Grossman, LLC is investigating potential securities fraud claims against Corcept Therapeutics Incorporated.
- The investigation concerns possible breaches of federal securities laws.
- The focus is on statements made by Corcept regarding the commercial potential of Korlym and the Company’s financial performance.
- Affected investors may be able to recover their losses through a securities class action lawsuit.
- The investigation could have far-reaching implications for the biopharmaceutical industry.
- Investors who believe they may have lost money as a result of Corcept’s alleged securities law violations are encouraged to contact Bronstein, Gewirtz & Grossman, LLC.
